Circulating Biomarkers for Diagnosis, Prognosis and Treatment Response Prediction in Cancer Patients, Part A, Volume 391 delves into the crucial role of circulating biomarkers in cancer diagnosis and treatment monitoring. Specific chapters in this new release include Circulating biomarkers for diagnosis and response to therapies in cancer patients, Identification of circulating tumor DNA as a biomarker for diagnosis and response to therapies in cancer patients, Identification of cell-free circulating epigenomic biomarkers for early diagnosis and response to therapies in breast cancer patients, Expanding frontiers in liquid biopsy-discovery and validation of circulating biomarkers in renal cell carcinoma and bladder cancer, and much more.

This comprehensive work explores the various types of biomarkers, their significance in early cancer detection, prognostication, and evaluation of therapeutic responses. It covers cutting-edge research on circulating tumor cells, cell-free DNA, exosomes, and other biomarkers that can revolutionize cancer management. Additionally, it discusses the challenges, advancements, and future prospects of utilizing circulating biomarkers in personalized cancer care.

• Provides a comprehensive overview of circulating biomarkers used in cancer diagnosis, prognosis, and treatment response monitoring
• Discusses the clinical utility of circulating biomarkers in early cancer detection, prognostication, treatment selection, and monitoring therapeutic responses
• Explores the latest technologies and methodologies for the detection, quantification, and analysis of circulating biomarkers in cancer patients